All Posts
Fight Against the Antibiotic Resistance in the Uncomplicated Urinary Tract Infections Market
Uncomplicated Urinary Tract Infections are one of the most commonly diagnosed infections in the US, with the maximum prevalence in women who are sexually active. A wide range o...
Angelman syndrome Pipeline: Unmet needs call for a robust pipeline
The necessity of a robust Angelman syndrome pipeline is indispensable at the current moment because of a shortage of any approved therapy option available in the market.The...
The New Buzz of Transcranial Stimulation Devices in the Neurological Disorders Market
Neurological disorders are one of the major causes of death and disability across the globe. As per the figures published in The Lancet journal for the Global Burden of Disease...
BlueRock secures FDA fast track; Omniscient rakes in $29M; Neuspera’s nerve implant gets a $65M b...
BlueRock Therapeutics secures FDA fast track for Parkinson’s disease cell therapyBlueRock, a Bayer subsidiary, is currently assessing the pluripotent stem cell-derived dopa...
Leading Autoimmune Diseases to Undergo Robust Improvement in Treatment by Major Pharma Companies
As per the American Autoimmune Related Diseases Association (AARDA), nearly 50 million people in the USA are affected by autoimmune diseases such as rheumatoid arthritis, psori...
MedTech Wrap Up
Neuros Medical Receives FDA Breakthrough Device Designation for its Novel Altius® High-Frequency Nerve Block SystemOn June 29, 2021, the US Food and Drug Administration (FD...
Cost-effectiveness, Advanced Technology, Rising Demand Pushes the Insulin Delivery Devices Market
Insulin is a hormone secreted by the beta cells of the islets of langerhans in the pancreas. The hormone is responsible for the maintenance of normal blood glucose levels by fa...
FemTech Market: With 100+ Startups in the domain, Women Healthcare is Witnessing a Huge Upliftment
Gender disparity is not new to ears. To look at all the corners, women have been and are still affected due to financial vulnerability, unequal access to education, and disprop...
Hepion aces mid-stage study; Bicycle Therapeutics-Ionis collaboration; Nimbus raises $105M; Regen...
Hepion Pharma's NASH drug is set for Phase 2b after clearing the safety barHepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing ...
Editor's Pick
Angelman syndrome Pipeline: Unmet needs call for a robust pipeline
The necessity of a robust Angelman syndrome pipeline is indispensable at the current mo...
The New Buzz of Transcranial Stimulation Devices in the Neurological Disorder...
Neurological disorders are one of the major causes of death and disability across the g...
Leading Autoimmune Diseases to Undergo Robust Improvement in Treatment by Maj...
As per the American Autoimmune Related Diseases Association (AARDA), nearly 50 million ...
Unity’s advanced vascular eye disease trial; Rallybio raises $100 M; Sa...
UNITY Biotechnology declares positive data from phase 1 clinical trial of UBX1325 in Ad...
Sign up For Newsletters
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
